Summary
Although oral MTX for the treatment of RA has been shown to be effective, adverse events may lead to discontinuation of treatment. This study reports the 24-week comparison of the safety and efficacy of subcutaneous (sc) vs orally administered MTX in patients with active RA.
- rheumatoid arthritis clinical trials
- © 2006 MD Conference Express